{"id":"W2149584982","doi":"10.1093/annonc/mdu574","title":"A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":99,"is_retracted":false,"has_abstract":false,"ca_institutions":"London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Cetuximab; Medicine; Internal medicine; Oncology; Clinical endpoint; Tolerability; Phases of clinical research; Head and neck cancer; Cancer; Mucositis; Randomized controlled trial; Chemotherapy; Colorectal cancer; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001341585,0.001906508,0.002794879,0.0004367811,0.000466546,0.001079995,0.001035468,0.001655109,0.006417607],"category_scores_gemma":[0.001072928,0.0008365617,0.001369221,0.0004661386,0.001481873,0.00127502,0.0004913159,0.003821658,0.001215617],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009745506,"about_ca_system_score_gemma":0.001580885,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001508845,"about_ca_topic_score_gemma":0.00389325,"domain_scores_codex":[0.9995989,0.0001698798,0.00002001922,0.00009235224,0.0000256403,0.00009318956],"domain_scores_gemma":[0.999443,0.0001197725,0.00008678359,0.00005521132,0.00002742184,0.0002678114],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9648465,0.009586896,0.0007852165,0.0003012614,0.0005597004,0.00004295962,0.00006996156,0.0008241242,0.004764532,0.0001755525,0.000931952,0.01711136],"study_design_scores_gemma":[0.9455141,0.05163774,0.001176452,0.000009683761,0.0002215045,0.0000282447,0.00002256286,0.0004107654,0.0004301181,0.0001181234,0.0004202958,0.00001037723],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909348,0.00149913,0.0004915188,0.0007564484,0.0004962895,0.002704702,0.0007870185,0.0001070649,0.002223043],"genre_scores_gemma":[0.9862853,0.001508331,0.001447311,0.001279778,0.0003136905,0.0027385,0.001664745,0.00003664464,0.004725679],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006417607,"threshold_uncertainty_score":0.021469,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03697488395085397,"score_gpt":0.3559445261094128,"score_spread":0.3189696421585588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}